Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02571049 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine
A Phase 2 study of Rapidly Escalating Migraine, sponsored by Dr. Reddy's Laboratories Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02571049: Completed Phase 2 study of Rapidly Escalating Migraine, sponsored by Dr. Reddy's Laboratories Limited.
NCT02571049 is a Phase 2 study of Rapidly Escalating Migraine that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02571049, a Phase 2 study of Rapidly Escalating Migraine, has completed, sponsored by Dr. Reddy's Laboratories Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Pilot study to compare the efficacy and safety of two strengths of injections of subcutaneous DFN-11 in subjects with rapidly escalating migraine headaches.
Conditions Studied
Interventions
- DRUG DFN-11
Study Locations (1)
Missouri
- Clinvest - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
What the finished NCT02571049 record still lists
NCT02571049 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Rapidly Escalating Migraine appearing as the primary indexed condition, and to 1 intervention - of which DFN-11 is the first listed.
NCT02571049 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT02571049 about?
NCT02571049 is a clinical study titled "Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine". Pilot study to compare the efficacy and safety of two strengths of injections of subcutaneous DFN-11 in subjects with rapidly escalating migraine headaches.
What is the current status of trial NCT02571049?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2015-09. Estimated completion is 2016-05.
What conditions does trial NCT02571049 study?
This clinical trial studies the following conditions: Rapidly Escalating Migraine.
What interventions are being tested in trial NCT02571049?
The interventions under investigation include: DFN-11 (DRUG).
Who is sponsoring clinical trial NCT02571049?
This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02571049 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02571049's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia